35 results about "Proteolipids" patented technology

This invention discloses a recombinant collagen liposome, its preparation method, and its application. The recombinant collagen liposome comprises 1-10 parts recombinant type XVII collagen, 2-15 parts soybean lecithin, 0.3-2 parts tocopherol, 0.5-7 parts antioxidant, 20-54 parts glycerol, and Dendrobium officinale enzymatic hydrolysate to a total weight of 100 parts. This invention improves the stability and transdermal absorption of recombinant type XVII collagen by encapsulating it in liposomes. The prepared recombinant collagen liposomes not only have a high encapsulation efficiency but also retain excellent barrier repair and anti-wrinkle effects after 8 weeks of storage, making them suitable for use in cosmetics.

The invention relates to the technical field of pharmaceutical compositions, and particularly discloses a proteolipid composite supplement with synergistic hangover alleviating and liver protecting functions and a preparation method thereof. The health-care food comprises the following components in percentage by mass: 10-25% of a Pu'er tea extract, 15-30% of glucose syrup, 5-15% of a hovenia acerba extract, 5-15% of a radix puerariae extract, 8-20% of corn peptide, 5-15% of oyster peptide, 3-10% of earthworm peptide, 1-5% of malic acid, 2-8% of multivitamins, 1-5% of an electrolyte compound, 3-10% of prebiotic fibers and 0.5-3% of gamma-aminobutyric acid. The compound vitamins comprise B1, B2, B6, B12, folic acid and vitamin C; the electrolyte compound is a nanoscale electrolyte compound and is an organic chelate containing potassium, magnesium and zinc; the prebiotic fiber is prepared by compounding galactooligosaccharide and resistant dextrin; through compounding design of active peptide components, plant active ingredients and functional factors, the active peptide improves the activity of key enzymes in ethanol metabolism in a targeted manner, and alcohol decomposition is accelerated.

The invention discloses a universal sample type nucleic acid releasing agent and application thereof. The nucleic acid releasing agent is prepared from the following components in molar concentration: 20 to 100 mM of Tris-HCl, 30 to 500 mM of sodium chloride, 30 to 200 mM of ammonium sulfate, 1 to 6 mM of EDTA (Ethylene Diamine Tetraacetic Acid), 1 to 8 mM of a reducing agent, 0.1 to 0.2 percent of sodium dodecyl sarcosinate, 0.1 to 3 mM of Surfactin, 5 to 30 percent of Chelex-100 and 5 to 15 percent of trehalose. According to the method, various samples can be mildly split, impurities such as impure proteins and lipids can be effectively removed, the complexity of nucleic acid samples is reduced, and the method is seamlessly jointed with subsequent PCR (Polymerase Chain Reaction); the kit has double effects of sample preservation and splitting decomposition, can strongly inhibit various nuclease, and can ensure the long-term storage stability of samples.

The present invention concerns a recombinant SARS-CoV-2 S glycoprotein trimer stabilized in a conformation that is anterior to the post-fusion conformation, as well as a proteoliposome comprising such a recombinant trimer and a vaccine based on such a proteoliposome. The invention also relates to a method of treating or preventing a SARS-CoV-2 infection in a subject using such a vaccine.

Disclosed are compositions including a population of human enteric neural stem cells (ENSCs), wherein the population comprises at least one of a cell expressing nerve growth factor receptor (NGFR), a cell expressing integrin alpha 6 (ITGA6), a cell expressing L1 cell adhesion molecule (L1CAM), a cell that expresses proteolipid protein 1 (PLP1), and / or a cell that expresses paired-like homeobox 2B (PHOX2B), methods of producing the compositions, and their uses.

Disclosed is a protein comprising no more than three human autoantigenic proteins, wherein a first human autoantigenic protein comprises a truncated myelin oligodendrocyte glycoprotein (MOG) amino acid sequence, a second human autoantigenic protein comprises a myelin basic protein (MBP) amino acid sequence, and a third human autoantigenic protein comprises a truncated proteolipid protein (PLP) amino acid sequence. Also disclosed are related nucleic acids, pharmaceutical compositions, methods of treating a demyelinating disease, and methods of producing the proteins.

The invention relates to bioinformatics and metabonomics, and discloses a human tissue lipid metabonomics multi-dimensional statistical analysis method, equipment, a medium and a product. Comprising the following steps: acquiring mass spectrometric detection original data and preprocessing to obtain a lipid quantitative data set; obtaining a first differential metabolite candidate set based on the lipid quantitative data set; determining a content change lipid set based on the significance parameters and the feature importance; performing feature selection on the content change lipid set, and screening to obtain lipid metabolite subsets meeting model performance evaluation index requirements to form a second differential metabolite set; the second differential metabolite set is subjected to correlation analysis with a metabolic pathway database and a protein-lipid interaction database, a multi-dimensional correlation analysis result containing the second differential metabolite set, metabolic pathway information and target protein information is output, and analysis from differential lipid to target protein is achieved.

The invention relates to a tooth whitening preparation based on a compound enzyme synergistic effect and application thereof, and belongs to the field of tooth whitening preparations, the tooth whitening preparation comprises the following substances by weight: 15-20 parts of esterase, 15-25 parts of lipase, 10-15 parts of papain, 10-15 parts of dextranase, and 25-50 parts of maltodextrin. Based on the characteristic that the oral pigment has a'protein-lipid-polyphenol 'composite structure, a quaternary synergistic effect mechanism is provided, protein, lipid-soluble and polyphenol pigments can be removed, and safe and efficient whitening is achieved in the oral environment with the pH of 6.0-7.5; the lipase, the esterase and the papain cooperate with one another, so that pigment matrixes can be decomposed; the dextranase directly acts to decompose water-insoluble glucan, carbohydrate pigments are reduced, decomposition of dental plaque and pigments thereof is accelerated, the lipase, the esterase, the papain, the dextranase and the laccase do not damage teeth, and teeth are not damaged while tooth whitening is achieved.

The application belongs to the technical field of biological medicine and functional cosmetics, and discloses acid-resistant collagen liposomes, a preparation method and application thereof. The liposome has a three-layer structure, and from inside to outside, it is sequentially a recombinant type III humanized collagen, a yolk lecithin-cholesterol lipid carrier core, and a sodium hydroxide-isopropyl alcohol system ultrasonic carboxymethylated chitosan surface modification layer. The modified chitosan has a substitution degree of 1.0-1.1 and a viscosity of 100-150 mPa·s. The preparation method is based on the film hydration method, and the liposome is prepared through basic liposome preparation, modified chitosan preparation and liposome surface modification. The freeze-dried powder can also be prepared through freeze-drying. The liposome is stable in a pH 1.0-6.0 acidic environment, can effectively protect the collagen from degradation, has antioxidant properties and no cytotoxicity, and the preparation process is easy to industrialize. The liposome can be used for preparing a pharmaceutical composition for treating digestive system diseases and repairing skin wounds, and a cosmetic composition for skin care, and has a wide application prospect.

The present invention provides compounds, methods, and pharmaceutical compositions for reducing the amount or activity of PLP1 RNA in cells or subjects, and, in some cases, the amount of proteolipid protein 1 in cells or subjects. [Solution] The present invention provides an oligomeric compound comprising a modified oligonucleotide consisting of 12 to 30 linked nucleosides, wherein the nucleic acid base sequence of the modified oligonucleotide is at least 85% complementary to equal-length portions of the PLP1 nucleic acid, and the modified oligonucleotide comprises at least one modification selected from modified sugar moieties and modified nucleoside-to-nucleoside bonds. Such compounds, methods, and pharmaceutical compositions are useful for improving at least one symptom or characteristic of leukodystrophy.

The invention provides an extraction method of fructus cannabis oil and the fructus cannabis oil, and particularly relates to the technical field of oil extraction. The extraction method comprises the following steps: adding fructus cannabis powder into an ionic liquid for soaking, carrying out ultrasonic extraction, and finally separating to obtain the fructus cannabis oil, wherein the ionic liquid is formed by choline derivatives and polybasic organic acid. According to the extraction method, the extraction efficiency and quality of the fructus cannabis oil are remarkably improved by adopting an ionic liquid and ultrasonic synergistic assistance technology. The ionic liquid effectively destroys a lignin-hemicellulose composite structure in fructus cannabis cell walls through hydrogen-bond interaction, increases the fluidity of a cell membrane lipid layer, forms micro-jet by combining with a cavitation effect generated by ultrasonic waves, promotes permeation of the ionic liquid and synergistically dissociates a protein-lipid complex, and realizes efficient release and dissolution of grease. And the used ionic liquid is non-toxic, degradable and recyclable, so that the production cost is remarkably reduced.

The invention belongs to the technical field of protein processing, and particularly relates to a purification method and application of lipoprotein lipase. The purification method of the lipoprotein lipase comprises the following steps: inserting a His tag into a coding gene of a lipase specific folding enzyme, preparing the lipase specific folding enzyme with the His tag, carrying out affinity purification, mixing the lipase specific folding enzyme with lipoprotein lipase, incubating, purifying again, and recovering the lipase specific folding enzyme to obtain the lipoprotein lipase. According to the purification method provided by the invention, the harm of a high-salt and high-imidazole environment to the protein in a traditional purification method can be avoided, the problem of protein aggregation in the purification process is solved, mild elution is realized, the inhibition effect of free lifO protein can also be avoided, and a new way is provided for simply, conveniently, efficiently and rapidly purifying the protein.

The invention provides application of lipoprotein lipase in promoting synthesis of rhamnolipid from pseudomonas aeruginosa, and belongs to the technical field of microbial fermentation. The invention provides an application of lipoprotein lipase in promotion of synthesis of rhamnolipid from pseudomonas aeruginosa (Pseudomonas aeruginosa), and a preparation method of the lipoprotein lipase in the promotion of synthesis of rhamnolipid from the pseudomonas aeruginosa (Pseudomonas aeruginosa). The lipoprotein lipase is lipoprotein lipase from pseudomonas aeruginosa. The traditional wild pseudomonas aeruginosa strain PAO1 needs more than 120 hours to achieve higher yield, while the method disclosed by the invention can achieve higher yield within 48 hours, so that the fermentation period is shortened by at least 50%, and the production time cost is greatly reduced. The method is simple and convenient, only the lipoprotein lipase needs to be exogenously added, the production cost can be reduced, and industrial requirements are met.

Disclosed is a protein comprising no more than three human autoantigenic proteins, wherein a first human autoantigenic protein comprises a truncated myelin oligodendrocyte glycoprotein (MOG) amino acid sequence, a second human autoantigenic protein comprises a myelin basic protein (MBP) amino acid sequence, and a third human autoantigenic protein comprises a truncated proteolipid protein (PLP) amino acid sequence. Also disclosed are related nucleic acids, pharmaceutical compositions, methods of treating a demyelinating disease, and methods of producing the proteins.

Provided here are compositions for delivery of leptin to a cell. The compositions can comprise a proteo-lipid vehicle comprising a recombinant fusion-associated small transmembrane (FAST) polypeptide and a nucleic acid encoding leptin or a functional fragment thereof. Also provided are methods for using the compositions.

The invention discloses a platycodon grandiflorum phosphomannose isomerase gene PgPMI as well as an encoded product and application thereof, and belongs to the technical field of platycodon grandiflorum genes. According to the invention, the platycodon grandiflorum phosphomannose isomerase gene PgPMI is cloned from platycodon grandiflorum, and the nucleotide sequence of the platycodon grandiflorum phosphomannose isomerase gene PgPMI is shown as SEQ ID NO. 1. According to the invention, the expression of the PgPMI gene in escherichia coli is successfully realized, and an enzymatic experiment verifies that the PgPMI has catalytic activity, so that mannose-6-phosphoric acid and fructose-6-phosphoric acid can be mutually converted, and a foundation is laid for revealing biosynthesis of platycodon grandiflorum polysaccharide. In addition, the platycodon grandiflorum phosphomannose isomerase can also be applied to biosynthesis pathways of plant ascorbic acid, cell walls, glycosylated proteins, lipoproteins, glycosyl phosphate inositol ankyrin and the like.

The application provides a tumor inhibiting composition and a preparation method and application thereof, and belongs to the technical field of medicines. After mesoporous carbon nanotubes are oxidized and chlorinated, oleanolic acid dithiocarbamate conjugate and (2-hydroxypropyl)-beta-cyclodextrin are coupled, drugs are loaded, a protein liposome solution is added, ultrasonic treatment is carried out, centrifugal separation is carried out, unloaded drug-loaded carbon nanotubes are removed, supernatant is freeze-dried, and the tumor inhibiting composition is prepared. The tumor inhibiting composition greatly improves the drug loading capacity of the nanosystem, the synergistic effect of multiple drugs, the anti-tumor effect, realizes the effects of targeting, slow and controlled release of drugs, improves the drug utilization rate, reduces the intake amount of drugs, reduces side effects, and improves the compliance of patients.

The invention provides a composition for red fading repair, which comprises an excipient, a polysaccharide polymer, a freshener, a humectant, a preservative and a liposome, and the liposome is a liposome formed by wrapping mussel mucin with phospholipid. The phospholipid-coated mussel mucin liposome in the composition can effectively promote skin barrier repair, significantly reduce erythema and inflammatory response, and achieve the effect of efficient red fading and repair.

The application relates to the fields of biological medicine and gene therapy, and discloses an IL1RN mRNA lipid nanoparticle drug and application thereof. The drug comprises a lipid nanoparticle and IL1RN mRNA encapsulated in the lipid nanoparticle; the IL1RN mRNA encodes a human IL1RN protein; and the lipid nanoparticle comprises ionizable lipids, phospholipids, cholesterol and pegylated lipids. The application encapsulates IL1RN-201 / 203 mRNA in conventional LNP for the first time, completes preparation characterization and in-vivo expression verification, and proves significant antitumor effect in a high-pressure tail vein transposon-induced in-situ KRAS mutant iCCA mouse model, and partial animals achieve complete tumor regression, thereby filling the blank in the field of IL-1 related inflammatory disease gene therapy and having outstanding originality and broad clinical conversion prospect.

The invention discloses an accurate energy control and fat reduction special diet composition based on homology of traditional Chinese medicine and food and a preparation method and application thereof.The composition is composed of soybean protein isolate, medium chain triglyceride, konjaku flour, inulin, white kidney bean extract, calcium beta-hydroxy-beta-methyl butyrate and other components, and a scientific formula is formed through accurate proportioning. The preparation method comprises the steps of raw material weighing, step-by-step mixing, granulation or homogenization treatment and the like, firstly, soybean protein isolate and medium chain triglyceride are mixed to prepare a basic protein and fat mixture, then other components are sequentially added, and finally the uniform and fine special diet composition is prepared. The special diet composition can accurately regulate and control energy intake, lipid metabolism is synergistically promoted through ingredients such as medium chain triglyceride, the konjaku flour, the inulin and the probiotics are utilized to enhance satiety and optimize intestinal health, meanwhile, the advantages of the medicinal and edible plant extracts are exerted, and the special diet composition has the effects of traditional Chinese medicine conditioning and modern nutrition.

Provided are compounds, methods, and pharmaceutical compositions for reducing the amount or activity of PLP1 RNA in a cell or subject, and in certain instances reducing the amount of proteolipid protein 1 in a cell or subject. Such compounds, methods, and pharmaceutical compositions are useful to ameliorate at least one symptom or hallmark of a leukodystrophy. Such symptoms and hallmarks include hypotonia, nystagmus, optic atrophy, respiratory distress, motor delays, cognitive dysfunction, speech dysfunction, spasticity, ataxia, seizures, choreiform movements, and death. Such leukodystrophies include Pelizaeus-Merzbacher disease.

The invention provides a microglial cell LPL targeted adeno-associated virus and application thereof in tauopathy treatment. An adeno-associated virus AAV vector is used for overexpressing lipoprotein lipase LPL in microglial cells to treat tau protein related neurodegenerative diseases. According to the present invention, the microglial cell specific promoter is introduced into the AAV vector, such that the human-derived LPL gene is precisely delivered to the microglial cells in the specific brain region of the central nervous system so as to achieve the lasting high-efficiency expression; according to the strategy, the decomposition capability of microglial cells on excessive lipid can be enhanced, lipid droplet load is reduced, and chronic inflammatory reaction is inhibited, so that vicious circle of lipid droplet deposition-inflammation-tau protein pathology aggravation is blocked.

The present application relates to agents capable of activating (GPR)124 / RECK / Frizzled / lipoprotein receptor-related protein (LRP)-mediated Wnt signaling, wherein said agents do not activate Frizzled / LRP –mediated Wnt signaling in the absence of RECK or GPR124, for use in the treatment and / or prevention of a bone-related disease or disorder in a subject.

The present application relates to a kind of microstructure supermolecular elastin, the microstructure supermolecular elastin includes liposome and supermolecular elastin and hydrolyzed elastin wrapped inside liposome;The membrane material of the liposome includes phospholipid and polyol.The present application creatively constructs an elastin liposome, supermolecular elastin and hydrolyzed elastin are co-encapsulated in the inside of liposome, can significantly improve the skin delivery depth of elastin, realize the efficient, safe transdermal delivery of macromolecular active protein;While supermolecular elastin and hydrolyzed elastin are mutually synergistic, can deeply penetrate skin, realize the effect of moisturizing and anti-wrinkle.

The application relates to bioinformatics and metabolomics, and discloses a human tissue lipid metabolomics multidimensional statistical analysis method, equipment, medium and product. The method comprises the following steps: obtaining mass spectrometry detection original data for pretreatment to obtain a lipid quantitative data set; based on the lipid quantitative data set, a first differential metabolite candidate set is obtained; based on a significance parameter and a feature importance, a content change lipid set is determined; feature selection is performed on the content change lipid set, a lipid metabolite subset meeting a model performance evaluation index requirement is screened, and a second differential metabolite set is formed; the second differential metabolite set is respectively associated with a metabolic pathway database and a protein-lipid interaction database for correlation analysis, and a multidimensional correlation analysis result containing the second differential metabolite set, metabolic pathway information and target protein information is output, so that analysis from differential lipids to target proteins is realized.

A multivalent tuberculosis vaccine comprises one or both Mycobacterium tuberculosis transmembrane copper transporters CtpV (SEQ ID NO: 1) and MctB (SEQ ID NO: 2) reconstituted into proteoliposomes at a protein-to-lipid ratio of 1:15 to 1:40 (w / w). The proteoliposomes, optionally combined in a 1:1 to 3:1 ratio and formulated with CpG ODN 2395, 7909, or 1018, are encapsulated in ZIF-8 or multivariate Mn-ZIF (15-50 % Mn) to yield shelf- stable nanoparticles. Intranasal or pulmonary administration elicits robust Thl-biased immunity, polyfunctional CD4+ T-cells, and IgG2a-dominant antibodies, achieving >0.3 login CPU reduction in lungs versus saline and superior Th1 / Th2 balance versus BCG in murine aerosol challenge models. A metalloimmunological adjuvant comprising CDA-loaded Mn-ZIF synergistically activates cGAS-STING, enhancing dendritic cell maturation and protective efficacy when combined with tuberculosis antigens. Kits and methods for vaccination and manufacture are provided.

The invention provides an expression cassette of lipoprotein lipase, a recombinant expression vector, a recombinant strain and application of the recombinant strain in production of lipoprotein lipase, and belongs to the technical field of gene engineering. The invention provides an expression cassette of lipoprotein lipase. The expression cassette comprises the following gene elements which are connected in series: an arabinose inducible promoter, double-copy lipoprotein lipase lipA and single-copy folded protein lipB. According to the invention, an expression element optimization strategy is adopted, an inducible promoter is adopted to replace a constitutive promoter to accurately regulate and control expression, and a specific site double-copy integration strategy and co-expression are combined to participate in protein folding genes, so that efficient secretory expression of lipoprotein lipase in host cells is realized.

An automated system for lipid exchange-mass spectrometry, e.g., measuring affinity of a membrane protein for lipids. The automated systems herein can measure the specificity of membrane protein-lipid interactions, detect remodeling of the membrane environment, and determine optimal lipid composition for membrane proteins.

Provided herein are compositions for delivering a molecular cargo to a cell or tissue of an eye. The composition may include lipids such as a cationic lipid, a helper lipid, an ionizable lipid, a PEGylated lipid, or cholesterol. Some embodiments include a fusion-associated small transmembrane (FAST) polypeptide. Also provided are methods for using the compositions. The method may include delivering a molecular cargo to a cell or tissue of an eye.

The invention discloses a safe and efficient transdermal natural collagen liposome, a preparation method and an anti-skin aging application thereof, and belongs to the technical field of biology. The collagen liposome is formed by wrapping natural collagen into a safe and stable liposome internal water phase, a safer stabilizer is innovatively used for replacing a traditional stabilizer cholesterol, and the stabilizer is covalently grafted with a polyethylene glycol chain, so that the basic function of the collagen liposome as a phospholipid membrane stabilizer can be effectively achieved; in addition, PEGylated phospholipid which is additionally added for endowing the long-cycle characteristic in a traditional nano preparation can be synchronously replaced, so that the formula composition of the whole system is simplified, and uncontrollable factors and potential complexity which are introduced by various auxiliary materials are reduced. The safe and efficient transdermal natural collagen liposome prepared by the invention can remarkably improve skin wrinkles and skin elasticity in a photoaging model, relieve skin lipid peroxidation and promote collagen regeneration, and can be applied to preparation of materials in the fields of cosmetic surgery and dermatology.